EBE – the European Trade Association representing biopharmaceutical companies of all sizes.
About EBE
10 Oct 2017

EBE and EFPIA call on the EU Commission and Member States to improve transparency on Hospital Exemptions for Advanced Therapies

“Therapies for the future - Exploring solutions for innovative treatments in Europe” will take place at the European Parliament  on 11 October 2017. In advance of this significant discussion...

Read more
27 Sep 2017

ARM, EBE, EFPIA and EuropaBio jointly publish a series of proposals to streamline requirements and accelerate approvals of clinical trials with new therapies that consist of or contain Genetically Modified Organisms (GMOs) in Europe

The Alliance for Regenerative Medicine (ARM), the European Biopharmaceutical Enterprises (EBE), the European Federation of Pharmaceutical Industries and Associations (EFPIA) and EuropaBio jointly publish a series of proposals to streamline requirements and accelerate approvals of clinical trials with new therapies that consist of or contain Genetically Modified Organisms (GMOs) in Europe....

Read more
29 Jun 2017

EFPIA, EBE and Vaccines Europe Back EU Leadership in Sustainable, Collaborative Fight Against AMR

The launch of the European Commission’s Action Plan on Antimicrobial Resistance (AMR) confirms the EU’s determination to take a leading role in combatting this phenomenon, by proposing concrete and innovative solutions to benefit patients worldwide....

Read more
10 Oct 2017

EBE and EFPIA call on the EU Commission and Member States to improve transparency on Hospital Exemptions for Advanced Therapies

“Therapies for the future - Exploring solutions for innovative treatments in Europe” will take place at the European Parliament  on 11 October 2017. In advance of this significant discussion...

Read more
27 Sep 2017

ARM, EBE, EFPIA and EuropaBio jointly publish a series of proposals to streamline requirements and accelerate approvals of clinical trials with new therapies that consist of or contain Genetically Modified Organisms (GMOs) in Europe

The Alliance for Regenerative Medicine (ARM), the European Biopharmaceutical Enterprises (EBE), the European Federation of Pharmaceutical Industries and Associations (EFPIA) and EuropaBio jointly publish a series of proposals to streamline requirements and accelerate approvals of clinical trials with new therapies that consist of or contain Genetically Modified Organisms (GMOs) in Europe....

Read more
18 Sep 2017

EBE-EFPIA Set Out Policy Positions in Their Personalised Medicines Manifesto

The EBE-EFPIA Personalised Medicine Working Group have developed a Manifesto that aims to highlight policy elements that are considered essential to ensure that personalised medicines and their paired diagnostic tests, also called companion diagnostics, successfully reach patients....

Read more
17 Nov 2017

Incentives, IP and smaller companies – the story of Vaxeal

Vaxeal Holding SA is headquartered in Vevey, Switzerland, with operations in Evry and Paris, France. The company was created in 2009. It develops therapeutic vaccines in combination with immune ch...

Read more
10 Nov 2017

Incentives, IP and smaller companies – the story of Chiesi and Holostem

Chiesi and Holostem Terapie Avanzate have jointly developed Holoclar, the first stem-cell-based product to be approved in Europe. Chiesi licenses the international marketing authorization for Holocl...

Read more
02 Nov 2017

Incentives, IP and smaller companies – the story of TiGenix

How TiGenix wants to change patients’ lives by improving health outcomes TiGenix NV (Euronext Brussels and NASDAQ: TIG) is an advanced Belgian biopharmaceutical SME with operations in Madrid, S...

Read more

From Twitter

#WeWontRest until we find shared solutions with all healthcare stakeholders to ensure #patients have timely access to innovative medicines @LillyPadEU https://t.co/Mq4MkYsLdu

EFPIA welcomes the future location of the @EMA_News decision has been made; now the focus must be on transition https://t.co/W4ttOKdm15

#WeWontRest in engaging with patients to make sure their voices are heard and their needs are addressed @BayerPharma https://t.co/qKGjXrL8yV

Follow us